Quironsalud Madrid
O custo da imunoterapia na Espanha geralmente varia de $12,000 a $25,000. Os preços variam dependendo do tipo de imunoterapia utilizada (tais como anticorpos monoclonais, inibidores de checkpoint ou terapia com células CAR-T), o número de ciclos de tratamento, a clínica e a expertise do médico responsável. Nos Estados Unidos, o preço médio é $30,000 (de acordo com a American Cancer Society). Isso significa que a imunoterapia na Espanha pode ser cerca de 38% mais barata do que nos EUA.
As clínicas espanholas geralmente incluem consulta inicial, testes diagnósticos, administração de medicamentos, monitoramento durante o tratamento e visitas de acompanhamento agendadas no custo total. Nos EUA, o preço listado geralmente cobre apenas a medicação, com cobranças separadas para consultas médicas, exames laboratoriais e serviços de infusão. Sempre confirme exatamente o que está incluído em cada clínica.
Por que escolher a Espanha para imunoterapia?
Acesse soluções avançadas de imunoterapia em clínicas de confiança [a partir de-custo].
| Turquia | Áustria | Espanha | |
| Imunoterapia | de $2,200 | de $30,000 | de $12,000 |
| Terapia com Bacilo de Calmette-Guérin (BCG) | de $1,200 | de $2,400 | de $3,200 |
| Terapia biológica | de $5,500 | de $20,000 | de $15,000 |
| Imunoterapia para o cancro do pulmão | de $18,000 | de $30,000 | de $30,000 |
| Imunoterapia para o cancro da próstata | de $12,000 | de $30,000 | de $35,000 |
A Bookimed não adiciona taxas extras aos preços de Imunoterapia. As tarifas vêm das listas oficiais das clínicas. O pagamento é feito diretamente na clínica na chegada.
A Bookimed está comprometida com sua segurança. Trabalha apenas com instituições que mantêm altos padrões internacionais em Imunoterapia e têm as licenças necessárias para atender pacientes internacionais em todo o mundo.
A Bookimed oferece assistência gratuita de especialistas. Um coordenador médico pessoal apoia antes, durante e após o tratamento, solucionando problemas. Nunca está sozinho em sua jornada de Imunoterapia.
O Dr. Graupera chefia o Departamento de Hematologia e Oncologia no Sant Joan De Déu – um dos principais hospitais infantis da Europa. Sua pesquisa foca nos tratamentos para o câncer pediátrico.
Dr. Lucía González Cortijo is a medical oncologist with more than 20 years of experience. She has led the Medical Oncology Department at Hospital Universitario Quirónsalud Madrid since 2020. Her focus areas include breast and gynecologic cancers. She also works in precision oncology, targeted therapies, and immunotherapy.
She has been Principal Investigator in more than 20 Phase II–III clinical trials. She has also served as sub-investigator in over 50 international trials. She previously worked at Quirónsalud Madrid from 2009 to 2020. Before that, she was at MD Anderson Cancer Center Madrid from 2002 to 2009.
She holds an MD and a PhD (cum laude) from the Autonomous University of Madrid. She completed her Medical Oncology specialty training at Hospital 12 de Octubre. She also earned a Master’s in Molecular Oncology. She is a member of SEOM, ESMO, ASCO, and GEICAM. She is a university lecturer.
Líder de renome mundial em Leucemia Linfocítica Crónica (LLC) – O Professor Bosch lidera mais de 80 ensaios clínicos sobre novos tratamentos.
Líder em pesquisa de imunoterapia para melanoma e câncer de mama – Dr. Soberino contribuiu para aprovações de medicamentos inovadoras que revolucionaram o tratamento.
Immunotherapy in Spain is safe due to strict European Union regulations and oversight by the Spanish Agency for Medicines and Health Products. Leading hospitals hold Joint Commission International accreditation and partner with American institutions like Memorial Sloan Kettering to deliver advanced checkpoint inhibitors and cellular treatments.
Bookimed Expert Insight: Spain’s oncology market is unique because its top private clinics, like Hospital Quiron Barcelona, are directed by globally reputed leaders who also head research at major public university hospitals. These specialists often lead over 80 active clinical trials simultaneously. This dual-role system ensures patients in private settings receive immunotherapy protocols that are identical to the latest experimental breakthroughs in university research labs.
Patient Consensus: Patients value the safety of university-affiliated centers like Hospital Clínic de Barcelona. Many recommend verifying full European Union accreditation to ensure the highest quality of biological products.
Spain provides advanced immunotherapy including checkpoint inhibitors like Pembrolizumab and Nivolumab, and cutting-edge CAR T-cell therapy. Licensed oncologists at JCI-accredited centers like Centro Médico Teknon and Quirónsalud treat melanoma, lung cancer, and hematological malignancies using these sophisticated biological protocols.
Bookimed Expert Insight: While public hospitals like Vall d’Hebron lead in trial eligibility, private centers offer faster access. Choosing a clinic within the HM Hospitales or Quirónsalud networks provides access to molecular profiling. This step is vital to qualify for off-label immunotherapy when standard treatments fail.
Patient Consensus: Patients value the speed of private clinics for accessing PD-1 inhibitors like Keytruda. They often suggest confirming drug approval via the Spanish Agency of Medicines (AEMPS) before traveling.
Patients typically stay in Spain for 3 to 12 weeks for initial immunotherapy cycles. While a full course can last up to 2 years, this shorter window allows oncologists at JCI-accredited centers like Centro Médico Teknon to monitor early responses and manage side effects.
Bookimed Expert Insight: Spain offers a unique advantage for complex cases through private networks like Quironsalud, which provide access to clinical trials. Patients often find that combining standard immunotherapy with these trials provides access to cutting-edge protocols not yet available in other regions.
Patient Consensus: Many families appreciate the specialized care at centers like SJD Barcelona, noting that the coordinated scheduling helps manage the emotional stress of international medical travel.
A good candidate for immunotherapy typically has advanced or treatment-resistant cancer with specific biomarkers like PD-L1 expression or high tumor mutational burden (TMB). Patients must have functional organs, a strong immune system, and no active autoimmune diseases to safely manage potential immune-related side effects.
Bookimed Expert Insight: While US immunotherapy averages $30,000, Spanish centers like Centro Médico Teknon offer these treatments starting from $12,000. Data shows patients save around 38% while accessing top-tier experts like Dr. Jesus Soberino, who specifically focuses on checkpoint inhibitors and clinical trials.
Patient Consensus: Patients emphasize requesting biomarker testing early, as these results are the primary gatekeeper for eligibility. Many suggest keeping physical copies of all imaging to speed up multidisciplinary reviews at private Spanish clinics.
Common immunotherapy side effects include fatigue, skin rashes, gastrointestinal issues like diarrhea, and joint pain. Spanish centers manage these through standardized Spanish Society of Medical Oncology protocols, using multidisciplinary committees and a 4-tiered severity grading system to provide personalized care.
Bookimed Expert Insight: Spanish centers like Hospital Quiron Barcelona and Centro Médico Teknon integrate specialized neuro-oncologists to manage rare neurological toxicities. This is a higher level of detail than standard oncology protocols. Expert doctors like Dr. Francesc Graus focus specifically on immune-mediated neurological complications, ensuring that even complex side effects are identified before they escalate.
Patient Consensus: Patients report that while fatigue is common, the most critical step is tracking energy and gastrointestinal changes daily. Early reporting to dedicated immunotherapy hotlines helps resolve symptoms before they require hospitalization.
Barcelona and Madrid are Spain's primary immunotherapy hubs, featuring world-class oncology centers like Centro Medico Teknon and MD Anderson Cancer Center Madrid. These cities host facilities specializing in checkpoint inhibitors, targeted therapies, and precision oncology under Joint Commission International (JCI) and European Society for Medical Oncology standards.
Bookimed Expert Insight: While Madrid and Barcelona dominate, Clinica Universidad de Navarra in Pamplona maintains a unique 74% bone sarcoma cure rate. High patient volumes at Barcelona clinics, like Teknon 23,500 annual operations, provide surgeons with exceptional experience in managing complex immunotherapy side effects.
Patient Consensus: Patients often find that private centers in Madrid and Barcelona offer faster access to clinical trials than public systems. Many recommend direct contact with major hospitals to navigate the local differences between standard protocols and emerging trial opportunities.
Immunotherapy is frequently combined with chemotherapy, radiation, or targeted drugs to enhance the immune system's response against tumors. Receiving these standard treatments in Spain does not disqualify you from future clinical trials, as many modern studies specifically recruit patients pre-treated with checkpoint inhibitors.
Bookimed Expert Insight: While public hospitals follow strict protocols, private centers like Quironsalud Madrid or Centro Médico Teknon often offer greater flexibility with bridge therapy. These institutions may allow concurrent chemo-immunotherapy while trial paperwork is processed, ensuring no treatment gaps. Leading Spanish oncologists, such as those at the Vall d’Hebron Institute of Oncology, frequently lead the very Phase I-III trials you may later join.
Patient Consensus: Patients emphasize keeping bilingual records of every dose and date, as trial coordinators require precise histories. Many found that rapid progression after combo therapy actually opened doors to specialized Phase I trials requiring refractory status.